Results of the Annual General Meeting

In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001 (Cth), Imagion Biosystems Limited advises the results its 2019 Annual…


Chairman's Address to Shareholders at Annual General Meeting

Imagion Biosystems announces the transcript of the Chairman's address to shareholders at the Annual General Meeting. Read the transcript.


Research Shows Imagion Nanoparticles Enable Low-field MRI

Imagion Biosystems Limited is pleased to share news of research published by collaborators from the University of Sydney demonstrating that Imagion’s iron…


Imagion to Work with Boston University of Next Generation Imaging Technology

Imagion Biosystems Limited (ASX: IBX) is pleased to announce it has become a member of the Nanosystems Engineering Research Center at Boston University,…


Imagion Biosystems Market Herald Interview

We recently announced plans to conduct our first in-human study for MagSense in Australia later this year. In this Market Herald interview, watch IBX CEO Bob…


Investor Webcast Presentation

Imagion Biosystems has released an investor webcast presentation announcement to the market. View the webcast presentation.


Imagion announces plan to undertake first clinical study in Australia

Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to announce its plans to…


Market Herald Interview

In May, Imagion signed a collaboration agreement with Siemens Healthineers to explore the utility of our MagSense nanoparticles as a contrast agent in MRI…


Imagion Nanoparticle Manufacturing Update

Imagion Biosystems Limited is pleased to report that the first phase of manufacturing of the MagSense™ HER2 nanoparticle formulation under Good…


Imagion Biosystems Establishes Collaboration with Siemens Healthineers

Imagion Biosystems Limited announces it has entered into a collaboration agreement with Siemens Healthcare Pty Ltd of Australia (Siemens Healthineers) to…